ARTICLE: Trialing precision medicine for type 2 diabetes
AUTHORS: Scott J. Pilla, Nestoras N. Mathioudakis & Nisa M. Maruthur
JOURNAL: Nature Medicine volume 29, pages309–310 (2023)
Abstract
Dissecting the heterogeneity of the type 2 diabetes (T2D) phenotype and combining this with precision medicine approaches is now recognized as the holy grail for truly improving diabetes care1. Major clinical recommendations emphasize that management must incorporate the individual characteristics of the person living with T2D — including, but not limited to, personal preferences, comorbid conditions and social context2. However, current algorithms for individualized medication selection are based predominantly on a few comorbid conditions only. Fortunately, evidence is accumulating on how to parse subgroups and individual characteristics relevant to prognosis and treatment selection, but examples of rigorous testing of individualized approaches to T2D management are lacking.
For the full article, click here.
